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Abstract: Aims: The relationship between variants in SLCO1B1 and SLCO2B1 genes and 
lipid-lowering  response  to  atorvastatin  was  investigated.  Material  and  Methods:  
One-hundred-thirty-six unrelated individuals with hypercholesterolemia were selected and 
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treated  with  atorvastatin  (10  mg/day/4  weeks).  They  were  genotyped  with  a  panel  of 
ancestry  informative  markers  for  individual  African  component  of  ancestry  (ACA) 
estimation  by  SNaPshot
®  and  SLCO1B1  (c.388A>G,  c.463C>A  and  c.521T>C)  and 
SLCO2B1 (−71T>C) gene polymorphisms were identified by TaqMan
® Real-time PCR. 
Results:  Subjects  carrying  SLCO1B1  c.388GG  genotype  exhibited  significantly  high  
low-density lipoprotein (LDL) cholesterol reduction relative to c.388AA+c.388AG carriers 
(41 vs. 37%, p = 0.034). Haplotype analysis revealed that homozygous of SLCO1B1*15 
(c.521C and c.388G) variant had similar response to statin relative to heterozygous and 
non-carriers. A multivariate logistic regression analysis confirmed that c.388GG genotype 
was associated with higher LDL cholesterol reduction in the study population (OR: 3.2, 
CI95%:1.3–8.0,  p  <  0.05).  Conclusion:  SLCO1B1  c.388A>G  polymorphism  causes 
significant increase in atorvastatin response and may be an important marker for predicting 
efficacy of lipid-lowering therapy. 
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1. Introduction 
Organic  anion  transporting  polypeptides  (OATPs)  are  plasma  membrane  transport  proteins  that 
mediate the active cellular influx of a variety of amphipathic compounds. OATP1B1, OATP2B1 and 
OATP1B3 are expressed in the sinusoidal membrane of hepatocytes and transport a large number of 
therapeutic drugs, such as statins [1]. The uptake of statins by OATPs not only represents the first step 
of hepatic drug elimination, but is also a delivery system to the liver as the target organ. Such transport 
therefore potentially influences the efficacy of the therapy of this drug class, as differences in OATP 
activity may result in variability of statins plasma levels and consequently variability in drug response. 
Atorvastatin  is  a  potent  inhibitor  of  the  3-hydroxy-3-methlyglutaryl-coenzyme  A  reductase 
(HMGCR), the rate-limiting enzyme in the cholesterol biosynthesis pathway [2]. It plays an important 
role  in  reducing  plasma  low-density  lipoprotein  (LDL)  cholesterol  and  in  preventing  the  risk  of 
coronary  artery  disease  (CAD)  [3,4].  Hepatic  uptake  of  atorvastatin  has  been  demonstrated  to  be 
mediated in an OATP-dependent manner [5]. 
OATP1B1 and 2B1 are codified by solute carrier organic anion transporter family genes, member 
1B1 (SLCO1B1) and 2B1 (SLCO2B1), respectively. SLCO1B1 has several common polymorphisms 
and  its relation with statin efficacy remains uncertain. The single  nucleotide polymorphism (SNP) 
SLCO1B1  c.521T>C  has  been  associated  with  markedly  increased  plasma  concentrations  of 
simvastatin,  rosuvastatin,  pravastatin,  and  atorvastatin  [6–12].  These  studies  have  shown  that 
homozygous  for  c.521C  allele  presented  the  highest  plasma  concentration  as  compared  to  TC 
heterozygote or TT homozygote. The increase in plasma concentration of statins may increase the 
exposure of the drug and lead to adverse drug reactions. Indeed, SLCO1B1*5 (c.521C) was associated 
with increased risk of statin-induced myopathy in a genome-wide association study in patients taking 
simvastatin 80 mg [13]. The SNP c.388A>G (SLCO1B1*1b) has been also associated with higher 
activity of OATP1B1 resulting in lower oral bioavailability of pravastatin [14]. Int. J. Mol. Sci. 2011, 12                       
 
5817 
Many  studies  have  focused  only  on  the  pharmacokinetics  of  statin,  whereas  the  impact  of  
SLCO1B1 genotypes on lipid-lowering response to statins remains unsure. In one study, in Japanese 
hypercholesterolemic  patients  treated  with  pravastatin  for  eight  weeks,  heterozygous  carriers  of 
SLCO1B1*15 allele (c.388G and c.521C alleles) had poor LDL cholesterol reduction as compared 
with  non-carriers  (reduction:  −14.1  vs.  −28.9%)  [15].  On  the  other  hand,  in  a  cohort  of  elderly 
hypercholesterolemic patients treated with fluvastatin extended-release, the SLCO1B1 c.463C>A SNP 
was significantly associated with enhanced fluvastatin response [16]. 
The potential contribution of genetic variations in SLCO2B1 in statins efficacy is not known. Until 
now, only one study has accessed the impact of variants of SLCO2B1; however, no differences were 
found  [7].  OATP2B1,  differently  from  OATP1B1  is  localized  not  only  in  hepatocytes,  but  at 
membranes  of  enterocytes,  human  skeletal  muscle  and  heart.  Recent  studies  have  suggested  that 
OATP2B1 may play a role in statin-induced myopathy, since the presence of OATP2B1 in primary 
muscle myoblast cells caused a significant increase in intracellular retention of statins [17]. 
The  uptake  and  delivery  of  atorvastatin  into  hepatocytes  by  OATP  is  essential  for  its  action. 
Because some studies have previously associated OATP variants with altered pharmacokinetic profile 
of  atorvastatin,  the  aim  of  this  study  was  to  describe  the  influence  of  SLCO1B1  and  SLCO2B1 
genotypes on the pharmacological efficacy of atorvastatin. 
2. Results and Discussion 
2.1. Characteristics of the Hypercholesterolemic Individuals 
Clinical  and  laboratory  data  of  the  HC  subjects  were  previously  described  by  
Rebecchi et al. (2009) [18]. Atorvastatin treatment significantly reduced total LDL cholesterol and 
triglycerides values (Table 1). Concomitant ingestion of CYP3A4 substrates or inhibitors did not affect 
atorvastatin response (p > 0.05), as evaluated by Chi-square test (data not shown). We did not observe 
an increase in high-density lipoprotein (HDL) cholesterol levels as it has been described for this drug. 
In addition, atorvastatin treatment did not cause a significant increase in CK levels. There was no 
report of intolerance or adverse effects related to atorvastatin therapy. We have observed an increase of 
ALT levels after treatment, but this increase did not translate into hepatotoxicity for the patients that 
have undergone atorvastatin treatment. 
Table 1. Biochemical profile of hypercholesterolemic individuals in response to atorvastatin 
(10 mg/day/4 weeks). 
Variables  Basal  Atorvastatin *  Change (%)  P 
TC (mg/dL)   281 ± 38  198 ± 30  −28.9 ± 9.5  <0.001 
LDL-C (mg/dL)  193 ± 55  118 ± 27  −38.3 ± 12.4  <0.001 
HDL-C (mg/dL)  56 ± 14  54 ± 13  −2.5 ± 10.5  <0.002 
TG (mg/dL)  160 ± 66  132 ± 52  −26.9 ± 52.5  <0.001 
CK (U/L)  102 ± 80  104 ± 88  4.9 ± 36.5  0.606 
ALT (U/L)  22 ± 10  25 ± 15  23.0 ± 63.2  <0.001 
ApoAI (g/L)  130 ± 25  136 ± 27  4.9 ± 15.4  0.013 
ApoB (g/L)  140 ± 22  102 ± 22  −28 ± 46.1  <0.001 
TC:  total  cholesterol,  LDL-C:  low-density  lipoprotein  cholesterol;  HDL-C:  high-density  lipoprotein  cholesterol;  TG:  triglyceride;  
CK: Creatine kinase; ALT: Alanine aminotransferase; ApoAI: Apolipoprotein AI; ApoB: Apolipoprotein B. * 10mg/daily for 4 weeks. Int. J. Mol. Sci. 2011, 12                       
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2.2. SLCO1B1 and SLCO2B1 Polymorphisms 
Genotype and allele frequencies for SLCO1B1 and SLCO2B1 polymorphisms were calculated for 
this  sample  of  the  Brazilian  population.  As  expected,  allele  frequencies  of  these  variants  were  in 
Hardy-Weinberg Equilibrium confirming the random selection of the individuals. The frequencies of 
the three variants (c.388A>G, c.463C>A and c.521T>C) for SLCO1B1 gene in Brazilian individuals 
were 32%, 16% and 12%, respectively. Minor allele frequency for SLCO2B1 −71C allele was 53%. 
Linkage  disequilibrium  was  tested  for  SLCO1B1  variants.  Association  was  found  between 
c.388A>G  and  c.521T>C  polymorphisms  (D'  =  0.84;  χ
2  =  9.56,  p  =  0.049)  and  c.388A>G  and 
c.463C>A SNPs were also consistently associated (D' = 1.0; χ
2 = 69.94, p < 0.0001). Nevertheless, 
c.521T>C  and  c.463C>A  were  not  associated  (χ
2  =  2.32,  p  =  0.677).  Therefore,  six  SLCO1B1 
haplotypes were found in our study group: *1a (39.3%), *1b (33.3%), *14 (16.0%), *15 (10.3%),  
and *4 (1.1%). 
The  frequency of SLCO1B1 and SLCO2B1 SNPs and of their  haplotypes  varies  largely  among 
ethnically identified populations [19–21]. Despite the fact that the described frequencies above for 
SLCO1B1 are similar to others previously reported [16,20], Brazilians are a highly admixed population 
with  Amerindian,  European  and  African  ancestral  roots  and  estimation  of  the  genetic  ancestry 
provided  by  AIMs  may  allow  more  realistic  representations  of  such  diversity  [22–25].  For  this 
purpose, we have estimated the ACA mean value for our sample and associated it with the alleles of 
SLC polymorphisms. 
The individual ACA values across the study population ranged from 0.003 to 0.989. ACA mean 
values between ancestral and variant allele of each SNP are presented in Figure S1. We observed that 
,only for SLCO2B1 −71T>C polymorphism, the ACA mean value was significantly higher in subjects 
carrying −71T allele compared to −71C allele carriers [0.461 (0.010–0.687) vs. 0.112 (0.037–0.243),  
p = 0.023]. 
Categorization of ACA values in four quartiles (<0.25; 0.25–0.50; 0.50–0.75; >0.75) revealed that 
frequency of the SLCO2B1 −71C allele decreased progressively from the lowest (<0.25 ACA) to the 
highest (>0.75 ACA) quartile, showing its higher prevalence in people with minor African influence 
(Supplemental Table 1). For SLCO1B1 gene, the frequencies of the SNPs were not different among the 
ACA quartiles.  
SLCO1B1 c.463C>A SNP showed a trend for decreasing the frequency of c.463A variant from low 
ACA values (<25%) to high ACA values (<75%) (Supplemental Figure 1, Supplemental Table 1). 
These results are in agreement with previous reports showing a low prevalence of this allele in 
African Americans and a high prevalence  in Caucasians [20]. For SLCO2B1 variant, a significant 
association  between  −71C  allele  and  ACA  values  was  found.  There  is  no  study  reporting  this 
relationship, but we may conclude that −71C allele varies among ethically identified populations and 
presents a low frequency in people with high African background. 
The  variables’  age,  BMI,  gender,  hypertension,  obesity,  menopause,  cigarette  smoking,  alcohol 
consumption, physical activity, and baseline mean plasma lipid parameters were not different among 
the genotypes or haplotypes for all the polymorphisms studied (data not shown). These results suggest 
that SLCO1B1 and SLCO2B1 variants were not associated with these variables in this sample.  Int. J. Mol. Sci. 2011, 12                       
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2.3. Effect of SLCO1B1 and SLCO2B1 Polymorphisms on Atorvastatin Response 
Results from one-way ANOVA regarding the effect of SLCO1B1 and SLCO2B1 SNPs on total and 
LDL cholesterol are presented in Table 2. For SLCO1B1 c.388A>G polymorphism, homozygous for 
c.388G allele presented higher mean percentage of LDL cholesterol reduction than carriers of c.388A 
allele (41.3 ± 12.4% for GG vs. 36.6 ± 12.1% for AA + AG, p = 0.034), in a dominant model. For 
SLCO2B1 polymorphism there was no association between lipid parameters and the genotypes. 
Table 2. Association of SLCO1B1 and SLCO2B1 variants with total and LDL cholesterol 
in individuals treated with atorvastatin. 
SNP 
Basal  Atorvastatin  Change (%) 
TC  LDL-C  TC  LDL-C  TC  LDL-C 
SLCO1B1             
c.521T>C             
TT (108)  281 ± 37  192 ± 34  199 ± 29  118 ± 26  28.7 ± 9.1  38.1 ± 12.4 
TC + CC (28)  282 ± 35  193 ± 31  192 ± 32  114 ± 28  31.8 ± 9.3  40.9 ± 11.6 
P  0.890  0.942  0.253  0.442  0.171  0.433 
c.388A>G             
GG (49)  279 ± 32  193 ± 36  193 ± 29  111 ± 25  30.6 ± 9.8  41.3 ± 12.4 
AA + AG (82)  280 ± 40  191 ± 28  200 ± 31  121 ± 27  28.0 ± 9.2  36.6 ± 12.1 
P  0.550  0.527  0.162  0.077  0.123  0.034 
c.463C>A             
CC (95)  283 ± 38  196 ± 35  199 ± 32  120 ± 27  29.4 ± 9.3  38.4 ± 11.5 
CA + AA (41)  271 ± 31  184 ± 27  194 ± 27  113 ± 26  27.9 ± 9.9  38.0 ± 14.4 
P  0.070  0.072  0.374  0.198  0.414  0.871 
SLCO2B1             
−71T>C             
TT (42)  281 ± 43  194 ± 37  200 ± 34  120 ± 28  28.6 ± 8.6  37.6 ± 10.6 
TC + CC (94)  282 ± 35  198 ± 29  198 ± 29  116 ± 27  29.4 ± 9.4  39.0 ± 12.9 
P  0.891  0.794  0.598  0.324  0.463  0.394 
Number  of  individuals is  given  in  parenthesis.  Values  are  mean  ±  standard  deviation.  P:  p-values  as  evaluated by  
one-way analysis of variance, significant p-values are indicated in bold. TC: total cholesterol (mg/dL); LDL-C: low-density 
lipoprotein cholesterol (mg/dL). 
In  addition,  the  effect  of  SLCO1B1  haplotypes  on  total  and  LDL  cholesterol  before  and  after 
atorvastatin treatment was investigated. We have compared the effect of *15 homozygous (*15/*15), 
*15 heterozygous (*1a/*15 and *1b/*15) and *15 non-carriers. (*1a, *1b, and *1a/*1b). Despite the 
fact that *15/*15 subjects presented lower total and LDL cholesterol reductions than *15 heterozygous 
and *15 non-carriers, this association lacked statistical significance (Figure 1). There was no effect of 
*14 allele on atorvastatin response. 
After atorvastatin treatment, LDL cholesterol serum concentrations varied largely from reduction of 
61.7% to 6.4%. Therefore, individuals with LDL cholesterol in the first quartile (reduction higher than 
48%) were compared with those with lower response. First, a stepwise forward multiple regression 
analysis including all parameters (age, BMI, gender, basal LDL cholesterol, and c.388A>G genotypes) 
was performed. After this analysis we concluded that BMI and gender were not related to atorvastatin Int. J. Mol. Sci. 2011, 12                       
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response.  Then,  a  multivariate  logistic  regression  including  all  the  remaining  parameters  was 
performed. Results from logistic regression showed that SLCO1B1 c.388GG and higher LDL basal 
levels were the most significant factors positively related to atorvastatin response (Table 3).  
Figure  1.  Influence  of  the  SLCO1B1  *15  variant  on  reduction  of  total  (TC)  and  
low-density  lipoprotein  (LDL-C)  cholesterol  in  response  to  atorvastatin 
(10 mg/day/4 weeks). P > 0.05, as compared by One-Way Analysis of Variance followed 
by Hom-Sidak test. Number of individuals in parenthesis. 
 
Table  3.  Multiple  logistic  regression  analysis  for  reduction  of  LDL  cholesterol  after 
atorvastatin treatment. 
Variables  p-value  Odds Ratio  95% CI  
Basal LDL cholesterol (≥208 mg/dL)  0.012  3.47  1.32–9.14  
Age (<60 years)  0.077  0.45  0.19–1.09  
SLCO1B1 c.388G allele (dominant)  0.012  3.23  1.30–8.04  
CI: Confidence interval; Significant values are highlighted in bold. LDL cholesterol reduction was considered higher than 
48% of the basal level. 
SLCO1B1  and  SLCO2B1  polymorphisms  may  have  particularly  important  consequences  for 
cholesterol-lowering  therapy  with  HMGCR  inhibitors,  as  OATPs  (1A2,  1B1,  1B3,  and  2B1)  are 
involved in the hepatic uptake of statins [5]. Current knowledge has shown that SNPs in SLCO1B1 
may result in reduced efficacy and increased risk of systemic exposure, leading to adverse effects [5].  
Studies of SLCO1B1 SNPs have focused mainly on c.521T>C polymorphism. They have shown 
that c.521C allele causes reduced OATP1B1 activity,  thus  increasing plasma concentrations of all 
statins except fluvastatin [6–12]. The area under the curve (AUC) of atorvastatin was 1.5–2.0-fold 
higher in subjects with the 521C/C genotype than in those with the 521T/T [6,7,9]. 
The effect of c.521T>C polymorphism on atorvastatin therapy has been investigated in this study. 
We have found no association between c.521C allele carriers and changes in lipid parameters after  
4 weeks of atorvastatin treatment. One reason for that lack of association may be due to a limited 
number  of  subjects  with  521C/C  genotype.  Because  only  two  individuals  in  our  sample  were 
homozygous for the variant allele they were pooled with the 521C/T genotype, then we could not 
effectively analyze the effect of 521C/C genotype.  Int. J. Mol. Sci. 2011, 12                       
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Some studies characterizing the impact of SLCO1B1 polymorphisms on lipid-lowering response 
have  been  conducted,  however  they  mainly  target  pravastatin  therapy  [15,26–30].  Because  these 
studies were very heterogeneous among the study population (healthy, hypercholesterolemic or elderly 
subjects),  duration  of  treatment  (single  dose,  3  or  8  weeks,  1  year)  and  daily  dose  (20,  40  or 
9.4 mg/day), divergent findings have been reported. For instance, Zhang et al. (2007) [30] reported an 
attenuated pravastatin (20 mg/day for 30 days) pharmacodynamic effect on total cholesterol in patients 
with 521TC heterozygous compared to 521TT homozygous. On the other hand, treatment with 40 mg 
pravastatin  for  3  weeks  caused  no  difference  in  lipid-lowering  efficacy  between  c.521C  carriers 
(i.e., SLCO1B1*15 and *17) and non-carriers (SLCO1B1*1a). 
The  SLCO1B1  c.463C>A  polymorphism  has  been  previously  associated  with  fluvastatin  
response [16].  Carriers of *14 allele had  better response to fluvastatin as compared to *1a/*1a or 
*1a/*14  genotypes.  We  have  found  no  association  between  c.463C>A  variant  and  atorvastatin 
response. In fact, this is not the first study to describe a lack of association between c.463C>A SNP 
and atorvastatin response. Thompson et al. (2005) [31] using a much larger sample (n = 1902) also did 
not find any association between this polymorphism and response to atorvastatin. The lack of effect of 
this polymorphism on atorvastatin response may be due to a substrate-specific effect of this OATP1B1 
variant. This substrate-specific effect has been clearly shown for SLCO1B1 c.521T>C SNP. It has been 
associated with a markedly reduced uptake of all statins except fluvastatin, as discussed before. Then, 
it is possible that SLCO1B1 c.463C>A variant has a high affinity for fluvastatin, however it needs to 
be verified by transporter function analyses. 
Significantly high reduction of LDL cholesterol in response to atorvastatin treatment was found in 
individuals  homozygous  for  SLCO1B1  c.388G  allele  when  compared  to  c.388A  allele  carriers  
(−41.3 vs. −36.6%). This finding is consistent with previous in vivo studies reporting a higher transport 
function  for  OATP1B1  in  subjects  carrying  *1b  variant,  resulting  in  lower  oral  bioavailability  of 
pravastatin [8] and pitavastatin [32].  
There  is  some  evidence  that  SLCO1B1*15  variant  (c.388G  and  c.521C)  exhibits  reduced  
transport function and play an important role in pravastatin and atorvastatin systemic exposure and 
elimination [6,33–35]. Lee et al. (2010) [35] have shown that the AUC of atorvastatin was 1.8 higher 
in *15/*15 subjects than in 1a/*15 and *1b/*15 and 2.2-fold than for *1a/*1a, *1a/*1b and *1b/*1b. 
Haplotype analysis revealed that mean percentage reduction in total and LDL cholesterol values at  
4  weeks  post-treatment  with  atorvastatin  were  lower  in  *15/*15  than  in  *15  heterozygous  and  
*15 non-carries. The allele frequency of SLCO1B1*15 was 10.3% in our population, then the sample 
size  was  not  enough  to  find  many  subjects  carrying  *15/*15  genotype,  so  the  association  lacks 
statistical  significance.  Multiple  regression  analysis  in  the  study  population  revealed  that  only 
c.388GG was correlated with statin response. 
With respect to SLCO2B1 polymorphism we have not found significant differences between the 
different genotypes and atorvastatin response. A previous study also failed to find relationship between 
polymorphisms of SLCO2B1 and pharmacokinetics of pravastatin [7].  Int. J. Mol. Sci. 2011, 12                       
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3. Material and Methods 
3.1. Subjects and Study Protocol 
The  characteristics  of  study  design  have  been  previously  reported  [18].  Briefly,  136 
hypercholesterolemic (HC) individuals were selected randomly among the outpatients evaluated for 
the presence of risk factors for coronary artery disease (CAD) at the University Hospital of the Sao 
Paulo University (Sao Paulo City, Brazil). The study protocol was approved by the Ethics Committee 
of this institution as well the Committee of the Faculty of Pharmaceutical Sciences (University of Sao 
Paulo).  Individuals  diagnosed  with  thyroid,  liver  and  kidney  diseases,  diabetes,  and  triglycerides 
higher than 400 mg/dL or subjects under treatment with lipid-lowering drugs, hormone replacement or 
oral  contraceptives  were  not  included.  Pregnant  women  or  patients  with  heart  disease  known 
previously were not included too. 
Information  on  age,  body  mass  index  (BMI),  gender,  hypertension,  obesity,  menopause  status, 
cigarette smoking, physical activity, alcohol consumption and family history of CAD were recorded.  
HC patients with (LDL) cholesterol higher than 160 mg/dL, even after a low cholesterol diet during 
4 weeks, were started on atorvastatin therapy, 10 mg orally once daily for 4 weeks. At the end of the 
protocol, the patients had a last appointment with the doctor and response to atorvastatin as well as any 
possible adverse reactions was evaluated. The study design was based on the recommendations of the 
National Cholesterol Education Program (NCEP) for treatment of high blood cholesterol in adults [36]. 
The dose of 10 mg atorvastatin was chosen because the patients had  moderate elevations of LDL 
cholesterol, and LDL cholesterol goal will be achieved with low doses for these patients. In addition, 
the NCEP recommend checking the response to drug therapy in about 6 weeks. 
Response to atorvastatin was evaluated by reduction of LDL cholesterol after the treatment, and 
adverse  effects  were  monitored  by  measuring  creatine  kinase  (CK)  and  alanine  aminotransferase 
(ALT) enzymes.  
3.2. Biochemical Profile and SLCO Variants Genotyping  
Blood samples for biochemical profile (lipids, CK, and ALT) measurements and genomic DNA 
extraction were collected after an overnight fast, one day before and 4 weeks after atorvastatin treatment. 
All patients followed exactly the same study protocol. Laboratory methods for biochemical parameters 
are described elsewhere [18].  
Genomic  DNA  was  extracted  from  EDTA-anticoagulated  blood  by  a  salting-out  procedure 
optimized in our laboratory [37]. Polymorphisms of SLCO1B1 [c.521T>C (Val174Ala, rs4149056), 
c.388A>G (Asp130Asn, rs2306283), c.463C>A (Pro155Thr, rs11045819)], and SLCO2B1 [−71T>C 
(rs2851069)]  were  detected  by  TaqMan
®  Real  time  PCR.  TaqMan  Drug  Metabolism  Genotyping 
Assay (20X) were obtained from Life Technologies (Foster City, CA, USA).  
PCR assays contained 4 μL of Universal Master Mix (2X) (Life Technologies), 0.4 μL of TaqMan 
Drug Metabolism Genotyping Assay (20X) and 3.6 μL de DNA (20 ng) diluted in nuclease-free water. 
The thermal cycling protocol consisted of initial cycle at 10 min a 95 °C followed by 40 cycles at 92 °C 
for 15 s, 60 °C for 1 min, using standard 7500 conditions. For SLCO2B1 polymorphisms the cycles 
were increased to 50, and the time for extension was 90 s. The amplification was carried out in a  Int. J. Mol. Sci. 2011, 12                       
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7500  fast  real-time  system  (Life  Technologies).  Genotype  calling  was  performed  using  the  SDS 
software (Life Technologies).  
3.3. Ancestry Informative Markers (AIMs) 
The ancestral origin and African component ancestry (ACA) of the individuals was explored using 
a 34-plex AIM-SNPs assay. SNPs were genotyped by multiplex-PCR followed by 34-plex SNaPshot
® 
primer extension reactions (Life Technologies, Foster City, USA). Extension products were separated 
by capillary electrophoresis (3130 Analyzer, Life Technologies) and POP6™ polymer (details in [38]). 
The  ACA  of  the  samples  was  estimated  and  categorized  into  four  ancestral  categories  (<0.25;  
0.25–0.50; 0.50–0.75; >0.75) according to the relative contribution of a variable number of African 
ancestral population.  
3.4. Statistical Analysis 
For  SLCO1B1,  as  previously  described  by  Tirona  and  colleagues  (2002)  [39],  haplotypes  
were defined based on the presence of c.388A>G, c.463C>A and c.521T>C polymorphisms alone  
or in combination, as follows: SLCO1B1*1a (wild type), *1b (c.388G), *4 (c.463A), *5 (c.521C),  
*14 (c.388G and c.463A) or *15 (c.388G and c.521C). The agreement of genotypes frequencies with 
Hardy-Weinberg equilibrium expectations was tested by χ
2 test using Haploview software. Relationships 
between the genotypes or haplotypes and categorical variables were evaluated by the Chi-square or 
Exact Fisher test.  
Continuous variables are presented as mean ± SD. Those without normal distribution were analyzed 
by a non parametric test, and they are presented as median (25%–75%). Numerical variables were 
compared by t test (two variables) and One-way ANOVA (three or more variables) and Holm-Sidak 
method  was  used  for  multiple  comparisons.  Logistic  regression  analysis  was  used  to  evaluate the 
relationships between reduction of serum LDL cholesterol and other variables after treatment with 
atorvastatin. Statistical tests were performed using the Sigma Stat version 3.5 (SPSS Inc., Chicago, IL, 
USA). Significance was considered P < 0.05. 
4. Conclusions 
The lack of association between lipid response to atorvastatin and SLCO1B1 c.521T>C polymorphism 
may be due to the size of our sample since we could not find many individuals homozygous to the rare 
allele. This caused the statistical power of the test performed to be below the desired level. In addition, 
the positive association between c.388GG carriers and higher LDL cholesterol reductions would be 
greatly strengthened if the sample were larger. 
SLCO1B1 c.388A>G polymorphism causes significant increase in atorvastatin response and may be 
an important marker for predicting efficacy of lipid-lowering therapy. However, others factors, such as 
the  drug  given  to  the  patient,  duration  of  the  treatment,  daily  dose,  basal  LDL  cholesterol,  may 
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